Cargando…

Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model

AIM: A model of progressively endocrine-resistant breast cancer was investigated to identify changes that can occur in signaling pathways after endocrine manipulation. METHODS: The MCF7 breast cancer model is sensitive to estrogens and anti-estrogens while variant lines previously derived from wild-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moore, Kate M., Cerqueira, Vera, MacLeod, Kenneth G., Mullen, Peter, Hayward, Richard L., Green, Simon, Harrison, David J., Cameron, David A., Langdon, Simon P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Open Exploration 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7612628/ https://www.ncbi.nlm.nih.gov/pubmed/35441158 http://dx.doi.org/10.37349/etat.2022.00074

Ejemplares similares

A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen
por: Lebedeva, Galina, et al.
Publicado: (2012)

Estrogen Receptor Signaling in Cancer
por: Langdon, Simon P.
Publicado: (2020)

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer
por: Collins, Denis, et al.
Publicado: (2017)

HER2 and ERβ2 downregulate estrogen-responsive element-mediated transcription activity of ERα-positive cells in response to estrogen stimulation
por: Park, B-W, et al.
Publicado: (2005)

HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?
por: Batra, Atul, et al.
Publicado: (2020)

Distribution and Prognostic Significance of Estrogen Receptor α (ERα), Estrogen Receptor β (ERβ), and Human Epidermal Growth Factor Receptor 2 (HER-2) in Thyroid Carcinoma
por: Mishra, Anjali, et al.
Publicado: (2020)

Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer
por: Langdon, Simon P., et al.
Publicado: (2020)

NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies
por: Khalil, Hilal S., et al.
Publicado: (2016)

COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer
por: Glynn, Sharon A, et al.
Publicado: (2010)

Reply to Letter to Editor: “HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?”
por: Li, Shuai, et al.
Publicado: (2020)

A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells
por: Khalil, Hilal S., et al.
Publicado: (2016)

Apigenin, a Partial Antagonist of the Estrogen Receptor (ER), Inhibits ER-Positive Breast Cancer Cell Proliferation through Akt/FOXM1 Signaling
por: Pham, Thu Ha, et al.
Publicado: (2021)

Targeting estrogen to kill ER-positive and ER-negative breast cancer
por: Jordan, VC
Publicado: (2005)

Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity
por: Lindberg, Karolina, et al.
Publicado: (2011)

Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER
por: Girgert, Rainer, et al.
Publicado: (2019)

Functions and physiological roles of two types of estrogen receptors, ERα and ERβ, identified by estrogen receptor knockout mouse
por: Lee, Hye-Rim, et al.
Publicado: (2012)

A role for estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) in collagen biosynthesis in mouse skin
por: Markiewicz, Margaret, et al.
Publicado: (2012)

Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells
por: Thaler, Sonja, et al.
Publicado: (2017)

Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma
por: de Souza, Ana Amélia, et al.
Publicado: (2019)

The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer
por: Huang, Rui, et al.
Publicado: (2015)

Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?
por: Mery, Benoîte, et al.
Publicado: (2021)

The Co-Expression of Estrogen Receptors ERα, ERβ, and GPER in Endometrial Cancer
por: Hojnik, Marko, et al.
Publicado: (2023)

Effects of Estrogen, an ERα Agonist and Raloxifene on Pressure Overload Induced Cardiac Hypertrophy
por: Westphal, Christina, et al.
Publicado: (2012)

Nuclear receptor CAR-ERα signaling regulates the estrogen sulfotransferase gene in the liver
por: Yi, MyeongJin, et al.
Publicado: (2020)

A tale of two estrogen receptors (ERs): how differential ER-estrogen responsive element interactions contribute to subtype-specific transcriptional responses
por: Huang, Jing, et al.
Publicado: (2006)

Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer
por: du Rusquec, Pauline, et al.
Publicado: (2020)

Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation
por: Fox, Emily M, et al.
Publicado: (2013)

Expression of Estrogen Receptors (ER), Progesterone Receptors (PR) and HER-2/neu receptors in Endometrial Carcinoma and their associations with histological types, grades and stages of the tumor
por: Waqar, Samina, et al.
Publicado: (2018)

The Effects of Mono-(2-Ethylhexyl) Phthalate (MEHP) on Human Estrogen Receptor (hER) and Androgen Receptor (hAR) by YES/YAS In Vitro Assay
por: Kim, Da-Hye, et al.
Publicado: (2019)

The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
por: Narbe, Ulrik, et al.
Publicado: (2019)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Transcriptomic analysis identifies gene networks regulated by estrogen receptor α (ERα) and ERβ that control distinct effects of different botanical estrogens
por: Gong, Ping, et al.
Publicado: (2014)

Sprouty 2 Is an Independent Prognostic Factor in Breast Cancer and May Be Useful in Stratifying Patients for Trastuzumab Therapy
por: Faratian, Dana, et al.
Publicado: (2011)

Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network
por: Lebedeva, Galina, et al.
Publicado: (2012)

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
por: Bardia, Aditya, et al.
Publicado: (2021)

Pancreatic Insulin Content Regulation by the Estrogen Receptor ERα
por: Alonso-Magdalena, Paloma, et al.
Publicado: (2008)

Classical Estrogen Receptors and ERα Splice Variants in the Mouse
por: Irsik, Debra L., et al.
Publicado: (2013)

Xenoestrogens Alter Estrogen Receptor (ER) α Intracellular Levels
por: La Rosa, Piergiorgio, et al.
Publicado: (2014)

ERα expression in T lymphocytes is dispensable for estrogenic effects in bone
por: Gustafsson, K L, et al.
Publicado: (2018)

Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer
por: Yang, Wei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oc8n8a8gg4v1rji3uv48ietsok